Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

NCT03201913 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic ER+ Breast Cancer

Interventions

DRUG: TTC-352

Sponsor

TTC Oncology, LLC